The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells

Alarm anti-proteases are secreted locally in response to inflammation and have been shown to be elevated in cancers. Secretory leukocyte protease inhibitor (SLPI), an alarm anti-protease, is amplified in ovarian carcinoma and is induced and binds to and protects progranulin (prgn) in inflammation. W...

Full description

Saved in:
Bibliographic Details
Published in:Carcinogenesis (New York) 2008-03, Vol.29 (3), p.466-472
Main Authors: Simpkins, Fiona A., Devoogdt, Nick M., Rasool, Nabila, Tchabo, Nana E., Alejandro, Emilyn U., Kamrava, Mitchell M.R.N., Kohn, Elise C.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Carcinogenesis, carcinogens and anticarcinogens
Cell Line, Tumor
Cell Proliferation
Cell Survival - physiology
Culture Media, Conditioned
Female
Female genital diseases
Gene Silencing
Gynecology. Andrology. Obstetrics
Humans
Immunoprecipitation
Medical sciences
Microscopy, Confocal
Microscopy, Fluorescence
Neutralization Tests
Ovarian cancer
Ovarian Neoplasms - pathology
Recombinant Proteins - genetics
Recombinant Proteins - immunology
Recombinant Proteins - metabolism
RNA Interference
RNA, Small Interfering
Secretory Leukocyte Peptidase Inhibitor - genetics
Secretory Leukocyte Peptidase Inhibitor - immunology
Secretory Leukocyte Peptidase Inhibitor - physiology
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alarm anti-proteases are secreted locally in response to inflammation and have been shown to be elevated in cancers. Secretory leukocyte protease inhibitor (SLPI), an alarm anti-protease, is amplified in ovarian carcinoma and is induced and binds to and protects progranulin (prgn) in inflammation. We reported prgn is a survival protein in ovarian cancer and now hypothesize that SLPI/prgn would promote proliferation and survival. Neutralizing anti-SLPI antibody treatment of HEY-A8 and OVCAR3 ovarian cancer cells decreased cell number (P 
ISSN:0143-3334
1460-2180
DOI:10.1093/carcin/bgm212